Inhaled therapy in cystic fibrosis: Agents, devices and regimens

Breathe

Volumn 11, Issue 2, 2015, Pages 111-118

  Agent, Penny ^a   Parrott, Helen ^a  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; CIPROFLOXACIN; COLISTIMETHATE; COLISTIN; DORNASE ALFA; LEVOFLOXACIN; MANNITOL; MUCOLYTIC AGENT; TOBRAMYCIN;

AEROSOL; AGE; ARTICLE; CYSTIC FIBROSIS; DRUG EFFICACY; DRY POWDER INHALER; HUMAN; LUNG CLEARANCE; LUNG FUNCTION; META ANALYSIS (TOPIC); NEBULIZER; NUTRITION; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFLAMMATION; SPIROMETRY;

EID: 84937556147     PISSN: 18106838     EISSN: 20734735     Source Type: Journal    
DOI: 10.1183/20734735.021014     Document Type: Article

References (48)

1. Cystic Fibrosis Trust. Standards for the Clinical Care of Children and Adults with Cystic Fibrosis in the UK. 2nd Edn. London, Cystic Fibrosis Trust, 2011. www.cysticfibrosis.org.uk/media/82070/CD_Standards_of_Care_Dec_11.pdf
2. Heijermann H, Westerman E, Conway S, et al. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros 2009; 8: 295-315
3. Pryor JA, Main E, Agent P, et al. Physiotherapy. In: Bush A, Alton EWFW, Davies JC, et al. eds. Cystic Fibrosis in the 21st Century. Progress in respiratory research, Vol 34. Basel, Karger, 2006; p. 303
4. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365: 1663-1672
5. Latchford G, Duff A, Quinn J, et al. Adherence to nebulised antibiotics in cystic fibrosis. Patient Educ Couns 2009; 75: 141-144
6. Langman H, Orr A, McVean R, et al. Delivering a concentrated dose of colistin using adaptiveaerosol delivery reduces treatment time. J Cyst Fibros 2004; 3: S57
7. Denyer J, Prince I, Dixon E, et al. Evaluation of the Target Inhalation Mode (TIM) breathing maneuver in simulated nebulizer therapy in patients with cystic fibrosis. J Aerosol Med Pulm Drug Deliv 2010; 23: Suppl. 1, S29-S36
8. Conway S, Dodd M, Marsden R, et al. Comparison and compliance in cystic fibrosis patients using either a halolite AAD system or a conventional high output nebuliser. J Cyst Fibros 2002; S67
9. Mullinger B, Sommerer K, Herpich C, et al. Inhalation therapy can be improved in CF patients by controlling the breathing pattern during inspiration. J Cyst Fibros 2004; 3: S65
10. Frederiksen B, Koch C, Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997; 23: 330-335
11. Mearns MB. Aerosol therapy in cystic fibrosis. Arch Dis Child 1970; 45: 605-607
12. Hodson ME, Penketh ARL, Batten JC. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa in patients with cystic fibrosis. Lancet 1981; 2: 1137-1139
13. UK Cystic Fibrosis Registry. Annual Data Report 2013. Bromley, Cystic Fibrosis Trust, 2014. www.cysticfibrosis. org.uk/media/598466/annual-data-report-2013-jul14.pdf
14. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis inhaled Tobramycin Study Group. N Engl J Med 1999; 340: 23-30
15. Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002; 121: 55-63
16. Oermann CM, Retsch-Bogart GZ, Quittner AL, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010; 45: 1121-1134
17. McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008; 178: 921-928
18. Mukhopadhyay S, Singh M, Cater JI, et al. Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks. Thorax 1996; 51: 364-368
19. Denton M, Kerr K, Mooney L, et al. Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a paediatric cystic fibrosis center. Pediatr Pulmonol 2002; 34: 257-261
20. Govan JR. Insights into cystic fibrosis microbiology from the European tobramycin trial in cystic fibrosis. J Cyst Fibros 2002; 1: Suppl. 2, 203-208
21. Konstan MW, Geller DE, Minic P, et al. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr Pulmonol 2011; 46: 230-238
22. Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros 2011; 10: 54-61
23. Schuster A, Haliburn C, Doring G, et al. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 2013; 68: 344-350
24. Stass H, Nagelschmitz J, Willmann S, et al. Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study. Clin Drug Investig 2013; 33: 419-427
25. Geller DE, Flume PA, Staab D, et al. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011; 183: 1510-1516
26. Clancy JP, Dupont L, Konstan MW, et al. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax 2013; 68: 818-825
27. Ramsey B, Pulmozyme (rhDNase) Study Group. A summary of the results of the phase III multicenter clinical trial: aerosol administration of recombinant human DNase reduces the risk ofrespiratory tract infections and improves pulmonary function in patients with cystic fibrosis. Pediatr Pulmonol 1993; Suppl 9: 152-153
28. Fuchs HJ, Borowitz D, Christiansen D, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331: 637-642
29. Quan JM, Tiddens HA, Sy JP, et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001; 139: 813-820
30. Fitzgerald DA, Hilton J, Jepson B, et al. A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics 2005; 116: e549-e554
31. Wilson CJ, Robbins LJ, Murphy JM, et al. Is a longer time interval between recombinant human deoxyribonuclease (dornase alpha) and chest physiotherapy better? A multi-center, randomized crossover trial. Pediatr Pulmonol 2007; 42: 1110-1116
32. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006; 354: 229-240
33. Elkins M, Dentice R. Timing of hypertonic saline inhalation for cystic fibrosis. Cochrane Database Syst Rev 2012; 2: CD008816
34. Dentice R, Elkins M. Timing of dornase alfa inhalation for cystic fibrosis. Cochrane Database Syst Rev 2013; 6: CD007923
35. Bilton D, Robinson P, Cooper P, et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J 2011; 38: 1071-1080
36. Bilton D, Bellon G, Charlton B, et al. Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis. J Cyst Fibros 2013; 12: 367-376
37. Aitken ML, Bellon G, De Boeck K, et al. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomised study. Am J Respir Crit Care Med 2012; 185: 645-652
38. Dodd ME, Abbott J, Maddison J, et al. Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis. Thorax 1997; 52: 656-658
39. Cystic Fibrosis Trust. Standards of Care and Good Clinical Practice for the Physiotherapy Management of Cystic Fibrosis. 2nd Edn. London, Cystic Fibrosis Trust, 2011. www.cysticfibrosis.org.uk/media/82076/ cd-standards-of-care-physio-june11.pdf
40. van der Giessen LJ, de Jongste JC, Gosselink R, et al. RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatr Pulmonol 2007; 42: 624-630
41. Miles K, Lenaghan S, Blanch L, et al. The patient’s view of nebulised drugs: knowledge, adherence, and difficulties. J Cyst Fibros 2014; 13: Suppl. 2, S90
42. Quittner AL, Modi AC, Lemanek KL, et al. Evidence based assessment of adherence to medical treatments in pediatric psychology. J Pediatr Psychol 2008; 33: 916-936
43. Harrison MJ, McCarthy M, Fleming C, et al. Inhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF). J Cyst Fibros 2014; 13: 692-698
44. Bilton D, Nash EF, Peckham D, et al. An evaluation of treatment burden following initiation of TOBI Podhaler in patients with cystic fibrosis. J Cyst Fibros 2014; 13: Suppl. 2, S65
45. Daniels T, Goodacre L, Sutton C, et al. Accurate assessment of adherence: self-report vs electronic monitoring of nebulisers. Chest 2011; 140: 425-432
46. McNamara PS, McCormack P, McDonald AJ, et al. Open adherence monitoring using routine data download from an adaptive aerosol delivery nebuliser in children with Cystic Fibrosis. J Cyst Fibros 2009; 8: 258-263
47. Ball R, Southern KW, McCormack P, et al. Adherence to nebulised therapies in adolescents with cystic fibrosis is best on weekdays during school term-time. J Cyst Fibros 2013; 12: 440-444
48. Quittner AL, Zhang J, Marynchenko M, et al. Pulmonary medication adherence and health-care use in cystic fibrosis. Chest 2014; 146: 142-151